Suppr超能文献

全球范围内对燕麦 β-葡聚糖产品心脏健康声称的评估。

Global review of heart health claims for oat beta-glucan products.

机构信息

R Mathews & Associates, Hudson, Ohio, USA.

PepsiCo Inc, Barrington, Illinois, USA.

出版信息

Nutr Rev. 2020 Aug 1;78(Suppl 1):78-97. doi: 10.1093/nutrit/nuz069.

Abstract

Coronary heart disease (CHD) is the leading cause of death globally. Consumption of whole grains and cereal fiber, as part of a healthy diet, can lower the risk of CHD. Health claims on food products are effective in helping consumers select healthful diets. The US Food and Drug Administration was the first to approve a health claim, in 1997, between beta-glucan soluble fiber from whole oats, oat bran, and whole oat flour and reduced risk of CHD. Only a few countries have approved similar claims. Since 1997, a significant amount of additional evidence has been published on the relationship between oat beta-glucan and CHD. To assist other jurisdictions in potentially utilizing this claim, the full extent of data that supports this claim (ie, the evidence utilized by the US Food and Drug Administration to substantiate the claim, as well as the results of 49 clinical trials published since 1997) are reviewed here. The complexities involved in authoring evidence-based health claims, including the impact of processing on beta-glucan cholesterol-lowering efficacy in approving eligible beta-glucan products, are also discussed.

摘要

冠心病(CHD)是全球范围内的主要死亡原因。食用全谷物和谷物纤维作为健康饮食的一部分,可以降低 CHD 的风险。食品上的健康声称在帮助消费者选择健康饮食方面非常有效。美国食品和药物管理局于 1997 年首次批准了一项健康声称,即全燕麦、燕麦麸皮和全燕麦粉中的β-葡聚糖可溶性纤维与降低 CHD 风险之间的关系。只有少数几个国家批准了类似的声明。自 1997 年以来,已经发表了大量关于燕麦β-葡聚糖与 CHD 之间关系的额外证据。为了协助其他司法管辖区可能利用这一说法,这里审查了支持这一说法的全部数据(即美国食品和药物管理局用来证实这一说法的证据,以及自 1997 年以来发表的 49 项临床试验结果)。还讨论了撰写基于证据的健康声明所涉及的复杂性,包括加工对批准合格的β-葡聚糖产品的β-葡聚糖降胆固醇功效的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验